Cardiff Oncology Q2 cash $60.3M; CRDF-004 readout expected 2H 2024

Cardiff Oncology, Inc.

2024-Q2 EPS reported -$0.49 revenue$368,000

Cash and equivalents $60.3M as of June 30, 2024; runway to Q3 2025.
Net cash used in ops $9.2M in Q2 2024 vs $7.1M in Q2 2023.
Total operating expenses $12.7M for Q2 2024, up $0.4M YoY.
CRDF-004 trial for first-line RAS-mutated mCRC data readout expected in 2H 2024.
Preclinical data published on onvansertib + olaparib in olaparib-resistant ovarian cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.